AI System Expansion Approved, “Capital Multiplication Plan” Officially Launched

2025-06-17

On June 13, 2025, Professor José García, Head of Strategic Investments for Western Europe at Eaton Vance Group, visited the Group’s European headquarters to engage in in-depth discussions with senior leadership regarding the expansion of the AI-driven automated trading system and the full-scale launch of the annual Capital Multiplication Plan.

Technology Gains Regulatory Endorsement, Ushering in a New Era of Intelligent Trading

The AI-driven automated trading system developed by Eaton Vance Group has officially secured approval from the Spanish National Securities Market Commission (CNMV), the UK Financial Conduct Authority (FCA), and the U.S. Securities and Exchange Commission (SEC). This marks a significant milestone in regulatory compliance and technological validation, laying a robust foundation for large-scale implementation and market adoption.

Capital Multiplication Plan Moves into Execution Phase, Powered by AI Innovation

This year’s Capital Multiplication Plan has entered its final review phase with the Group’s Investment Division. At the core of the strategy lies the proprietary AI system, designed to drive intelligent decision-making, automated trade execution, and advanced quantitative risk control. These integrated capabilities aim to deliver a more efficient, precise, and scalable asset growth experience for all participants.

Technology Gains Regulatory Endorsement, Ushering in a New Era of Intelligent Trading

The AI-driven automated trading system developed by Eaton Vance Group has officially secured approval from the Spanish National Securities Market Commission (CNMV), the UK Financial Conduct Authority (FCA), and the U.S. Securities and Exchange Commission (SEC). This marks a significant milestone in regulatory compliance and technological validation, laying a robust foundation for large-scale implementation and market adoption.

Capital Multiplication Plan Moves into Execution Phase, Powered by AI Innovation

This year’s Capital Multiplication Plan has entered its final review phase with the Group’s Investment Division. At the core of the strategy lies the proprietary AI system, designed to drive intelligent decision-making, automated trade execution, and advanced quantitative risk control. These integrated capabilities aim to deliver a more efficient, precise, and scalable asset growth experience for all participants.

Disclaimer: This article is reproduced from other media. The purpose of reprinting is to convey more information. It does not mean that this website agrees with its views and is responsible for its authenticity, and does not bear any legal responsibility. All resources on this site are collected on the Internet. The purpose of sharing is for everyone's learning and reference only. If there is copyright or intellectual property infringement, please leave us a message.

Newest

1The First Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

The First Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

2The Second Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

The Second Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

3Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Singapore College of Traditional Chinese Medicine Sign Strategic Cooperation Framework Agreement on TCM Education and Exchange

Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Singapore College of Traditional Chinese Medicine Sign Strategic Cooperation Framework Agreement on TCM Education and Exchange

4Tianjiang Pharmaceutical, a Subsidiary of China TCM, Participates in the 4th CACM Specialized Disease Collaboration Platform Annual Conference & 10th Jiangsu Traditional Chinese Medicine Academic Conference

Tianjiang Pharmaceutical, a Subsidiary of China TCM, Participates in the 4th CACM Specialized Disease Collaboration Platform Annual Conference & 10th Jiangsu Traditional Chinese Medicine Academic Conference

5Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Federation of Chinese Medicine & Acupuncture Societies of Australia Sign Strategic Cooperation Framework Agreement

Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Federation of Chinese Medicine & Acupuncture Societies of Australia Sign Strategic Cooperation Framework Agreement

6MEXC Claims Dual Wins at BeInCrypto 100 Awards as Best Centralized Exchange and Best Exchange in LATAM

MEXC Claims Dual Wins at BeInCrypto 100 Awards as Best Centralized Exchange and Best Exchange in LATAM

©copyright2009-2020Fresh life